Evidence map›Paper›PMID 42423946›Full record

ReviewAdvances in therapy2026

An Eight-Century Evolution of Asthma Therapeutics in Western Countries: From Medieval Regimens to Anti-inflammatory Reliever Therapy and Precision Biologics.

Nestor A Molfino, Paul M O'Byrne

Abstract readReviewHistorical Article
In one paragraph

Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nestor A MolfinoClinical Development, Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, CA, USA. nmolfino@amgen.com.ORCID http://orcid.org/0009-0004-8553-9167
Paul M O'ByrneFaculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The changes in our understanding of asthma etiopathogenesis has led to new therapies and a significant reduction in asthma exacerbations as well as mortality. The management of asthma has evolved over several centuries from constitutional/environmental palliation, to the recognition of recurrent reversible airway obstruction and to the recognition of inflammatory changes in the lung compartment. The therapeutic armamentarium has also shifted from using alternative therapies at first, to bronchodilator rescue alone and then to inflammation-directed controller therapy with corticosteroids. In the 2000s, biomarker- and endotype-guided therapy with biologics started a major shift in our understanding of asthma which has generated new treatments and outcomes. This review summarizes how clinicians approached patients with the therapeutic armamentarium available in each era, and how those changes translated into success or failure in reducing exacerbations, hospitalizations, relapses, and mortality. The emphasis is on Western countries, where clinicians described, implemented, and quantified the principal modern therapeutic shifts.

Indexed as

Anti-Asthmatic AgentsAnti-Inflammatory AgentsAsthmaBiological ProductsAdrenal Cortex HormonesBronchodilator AgentsHistory, 19th CenturyHistory, 20th CenturyHistory, 21st CenturyHistory, MedievalHumansPrecision MedicineAdrenal Cortex HormonesAnti-Asthmatic AgentsAnti-Inflammatory AgentsBiological ProductsBronchodilator AgentsAnti-inflammatory reliever therapyAsthmaAsthma historyBiologicsBronchodilatorsHospitalizationInhaled corticosteroidsMortality

Identifiers

PMID42423946
PMCPMC13619785

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.